身高遗传学与房颤风险的孟德尔随机化研究
本研究采用孟德尔随机化方法,利用身高和房颤的大规模全基因组关联研究汇总数据,发现遗传预测身高每增加1个标准差,房颤风险显著增加(OR 1.34)。个体水平分析在Penn Medicine Biobank中验证了该关联,提示身高可能是房颤的因果风险因素。
要点
- 遗传预测身高每增加1-SD,房颤风险增加34%(OR 1.34)。
- 个体水平MR校正临床和超声心动图混杂后关联仍显著(OR 1.89)。
- 身高相关生物学通路可能为房颤治疗提供新靶点。
核心结论
- 身高可能是房颤的正向因果风险因素。
研究设计与样本
- 汇总水平孟德尔随机化分析使用身高GWAS(GIANT/UK Biobank;693,529人)和房颤GWAS(AFGen;65,446例病例和522,744例对照)。
- 个体水平分析在Penn Medicine Biobank的6,567名欧洲裔参与者中进行(入组中位年龄63岁,IQR 55-72;38%女性;招募于2008-2015年)。
主要发现
- 汇总水平MR显示,遗传预测身高每增加1-SD,房颤的比值比为1.34(95% CI 1.29至1.40;p = 5 × 10-42)。
- 个体水平MR显示,身高每增加1-SD,房颤的比值比为1.89(95% CI 1.50至2.40;p = 0.007),校正临床和超声心动图混杂因素后。
- 个体水平全表型关联研究确认了身高与房颤的既往观察性关联。
临床怎么用
- 身高或人体测量学风险因素可能用于改进房颤筛查和一级预防,但需进一步研究。
- 身高相关生物学通路可能为房颤治疗提供新靶点。
局限性
- 遗传变异的潜在多效性可能导致偏倚。
- 个体水平发现可能无法推广到非欧洲人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Observational studies have identified height as a strong risk factor for atrial fibrillation, but this finding may be limited by residual confounding. We aimed to examine genetic variation in height within the Mendelian randomization (MR) framework to determine whether height has a causal effect on risk of atrial fibrillation. METHODS AND FINDINGS: In summary-level analyses, MR was performed using summary statistics from genome-wide association studies of height (GIANT/UK Biobank; 693,529 individuals) and atrial fibrillation (AFGen; 65,446 cases and 522,744 controls), finding that each 1-SD increase in genetically predicted height increased the odds of atrial fibrillation (odds ratio [OR] 1.34; 95% CI 1.29 to 1.40; p = 5 × 10-42). This result remained consistent in sensitivity analyses with MR methods that make different assumptions about the presence of pleiotropy, and when accounting for the effects of traditional cardiovascular risk factors on atrial fibrillation. Individual-level phenome-wide association studies of height and a height genetic risk score were performed among 6,567 European-ancestry participants of the Penn Medicine Biobank (median age at enrollment 63 years, interquartile range 55-72; 38% female; recruitment 2008-2015), confirming prior observational associations between height and atrial fibrillation. Individual-level MR confirmed that each 1-SD increase in height increased the odds of atrial fibrillation, including adjustment for clinical and echocardiographic confounders (OR 1.89; 95% CI 1.50 to 2.40; p = 0.007). The main limitations of this study include potential bias from pleiotropic effects of genetic variants, and lack of generalizability of individual-level findings to non-European populations. CONCLUSIONS: In this study, we observed evidence that height is likely a positive causal risk factor for atrial fibrillation. Further study is needed to determine whether risk prediction tools including height or anthropometric risk factors can be used to improve screening and primary prevention of atrial fibrillation, and whether biological pathways involved in height may offer new targets for treatment of atrial fibrillation.
引用
- Levin MG, Judy R, Gill D, et al. Genetics of height and risk of atrial fibrillation: A Mendelian randomization study. PLoS Med. 2020. PMID: 33031386. doi:10.1371/journal.pmed.1003288
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。